Malik Bisserier

This study shows that blocking IL-6 restores FOXP3 expression in PAH, revealing its role as a biomarker and therapeutic target.

This study shows that Sotatercept reverses SIN3a deficiency-driven pulmonary arterial hypertension by reprogramming BMPR2/TGF-β-HIF-1α signaling pathways.

This study identifies epigenetic activation of Smurf1 via EP300-mediated H3K27ac as a driver of BMPR2 signaling disruption in PAH, showing therapeutic potential through Smurf1 inhibition.

This study shows that inhibiting Epac1 with AM-001 reduces fibroblast proliferation and profibrotic markers, protecting against pulmonary fibrosis in mouse models and human lung slices.